Our News

 

 

Groupe SYNERLAB is taking on the objective to grow steadily in today’s challenging market, in order to assert its position as a leading European CDMO.

President Pierre Banzet has been striving to develop key solutions to provide our clients with best-in-class products and implemented actions to structure the Group around the six production sites in France and Spain in accordance with an operational excellence goal. These efforts paved the way for SYNERLAB’s future growth.

A new phase will start with a new management to further accelerate the Group’s development. Pierre Banzet will not have an executive role anymore but will keep on sharing his experience by joining the Supervisory Board.

As current General Manager of Groupe SYNERLAB and driven by my commitment to SYNERLAB’s values, Bruce will take on these responsibilities and will be appointed as the new CEO. He will strive to sustain the quality of products and services we have built over the last 45 years while improving the Group’s performance.

April 2019

 

Interview Pierre Banzet

CEO Groupe SYNERLAB

By Crystelle Coury, PharmaBoardroom –

(Feb. 2019)

Enjoy your reading!

SERIALIZATION IS UP AND RUNNING!

 

Enjoy your reading!

 

GROUPE SYNERLAB WELCOMES A NEW

GENERAL MANAGER

 

 Enjoy your reading!

UNDERSTANDING  THE CHALLENGES IN DESIGNING & EXECUTING CLINICAL TRIALS FOR SCREENING TESTS!

From Isabelle DECORTE, Head of Pharmaceutical Development & Operations, QP at Synerlab Développement, Orléans

 Enjoy your reading!

OUR NEW EQUIPMENTS

Great visibility of Groupe SYNERLAB in  DOSES 71  dd. May 2018.

Enjoy your reading!

WE ARE SYNERLAB, NICE TO MEET YOU

Glad to let you know more about SYNERLAB

SYNERLAB DÉVELOPPEMENT

INVESTMENTS FOR COMPLEX FORMULATIONS

Specialized in pre-formulation to industrialization pharma development, Synerlab Développement develops oral solid forms by taking into account the regulatory, technical, therapeutic, commercial and insutrial exigencies. In order to adapt to the new formulation challenges posed by the higher number of increasingly complex molecular entities, Synerlab Développement has acquired hot extrusion equipment. This technology improves the bioavailability of active ingredients by adapting its release profile. For the purpose of developing with limited amounts of active ingredients drugs of major therapeutic interest that require quick clinical evaluation, the contract manufacturer has acquired a filling system that allows  the manufacture of low-close capsules of vials.